Clinical Trial Update: Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA) [Phase 3]

View source ↗

Summary

A Phase 3 trial update reports MRI-verified early response to certolizumab pegol in subjects with active rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CIMZIA (CERTOLIZUMAB PEGOL)

Snippet

Sponsor: UCB Pharma | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2014-02-05